Breast Cancer at ASCO: Latest Trial Results and Emerging Therapies
Kimberly Blackwell, MD1
, June 21, 2012
CancerNetwork and the journal ONCOLOGY present an exclusive interview with Dr. Kimberly Blackwell, Duke Cancer Institute, who discusses some of the most important information to come out of this year’s meeting and talks about the future of breast cancer research.
ASCO: 'New, Exciting Era' for Research and Treatment of CLL
Hagop Kantarjian, MD1
, June 18, 2012
CancerNetwork speaks with Hagop Kantarjian, MD, M.D. Anderson Cancer Center, who shares his impressions of some of the highlights of this year’s ASCO meeting with regard to hematologic malignancies.
ASCO: Ponatinib Provides New Option for Heavily Treated Patients With CML
, June 12, 2012
Updated clinical data from the pivotal phase II global PACE trial of ponatinib confirm its impressive antileukemic activity in patients with chronic myeloid leukemia or Philadelphia-chromosome-positive acute lymphoblastic leukemia at all stages who are resistant or intolerant to dasatinib or nilotinib.
ASCO: AE37 Peptide Vaccine May Help Prevent Breast Cancer Recurrence
Anna Azvolinsky, PhD
, June 11, 2012
Women previously treated for HER2-positive breast cancer have lower rates of relapse when given a novel peptide vaccine. The AE37 vaccine showed a 43% risk reduction in these patients after 22 months of follow-up in a phase IIb clinical trial.
Melanoma at ASCO: Latest Treatments and Emerging Therapies
Michael B. Atkins, MD1
, June 11, 2012
In this exclusive interview, Michael B. Atkins, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses some of the most important melanoma research to come out of this year’s ASCO meeting and talks about the future of melanoma therapies.